Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALA-1000
- Development stage
- Approved
- Lead developer
- Alar Pharmaceuticals
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Subcutaneous
01
Overview
ALA-1000 is a long-acting, sustained-release injectable prodrug formulation of buprenorphine developed for the treatment of opioid use disorder (OUD) and potentially chronic pain. It utilizes Alar Pharmaceuticals' proprietary In-Relar sustained release drug delivery platform to provide therapeutic levels of buprenorphine for up to three months following a single subcutaneous injection. This extended duration aims to improve patient compliance, reduce the risk of misuse or accidental exposure, and address unmet needs in OUD management by offering less frequent dosing options. Clinical studies have demonstrated favorable safety, tolerability, and pharmacokinetic profiles with low initial burst and no dose dumping effect. The drug is currently advancing toward Phase III clinical trials[1][2][3][5][8].
- Brand names
- SublocadeBrixadiBuvidal
- Other names
- ALA-1000ALA1000ALA 1000
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on ALA-1000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALA-1000.